A phase II safety and efficacy study of the vascular endothelial growth factor receptor tyrosine kinase inhibitor pazopanib in patients with metastatic urothelial cancer
Roberto Pili, Rui Qin, P. J. Flynn, Joel Picus, Michael Millward, Wing Ming Ho, Henry Pitot, Winston Tan, Kiersten M. Miles, Charles Erlichman, Ulka Vaishampayan
Dive into the research topics of 'A phase II safety and efficacy study of the vascular endothelial growth factor receptor tyrosine kinase inhibitor pazopanib in patients with metastatic urothelial cancer'. Together they form a unique fingerprint.